* fever or respiratory rate \>24/minute or oxygen saturation at room air\< 94% * any serious co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c \> 8%, chronic liver disease, lymphocyte count \<1,000cell/cu.mm. * history of ivermectin or any of the study drug allergy. * concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin * pregnant or lactating woman

* fever or respiratory rate \>24/minute or oxygen saturation at room air\< 94% * any serious co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c \> 8%, chronic liver disease, lymphocyte count \<1,000cell/cu.mm. * history of ivermectin or any of the study drug allergy. * concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin * pregnant or lactating woman

- fever or respiratory rate >24/minute or oxygen saturation at room air< 94% - any serious co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c > 8%, chronic liver disease, lymphocyte count <1,000cell/cu.mm. - history of ivermectin or any of the study drug allergy. - concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin - pregnant or lactating woman

- fever or respiratory rate >24/minute or oxygen saturation at room air< 94% - any serious co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c > 8%, chronic liver disease, lymphocyte count <1,000cell/cu.mm. - history of ivermectin or any of the study drug allergy. - concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin - pregnant or lactating woman

- fever or respiratory rate >24/minute or oxygen saturation at room air< 94% - any co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c > 8%,bmi >35 kg/m2, chronic liver disease, lymphocyte count <1,000cell/cu.mm. - history of ivermectin or any of the study drug allergy. - concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin - pregnant or lactating woman

- fever or respiratory rate >24/minute or oxygen saturation at room air< 94% - any co-morbidity such as chronic lung disease, chronic kidney disease, cardiovascular diseases, arrythmia, diabetes mellitus with hba1c > 8%,bmi >35 kg/m2, chronic liver disease, lymphocyte count <1,000cell/cu.mm. - history of ivermectin or any of the study drug allergy. - concomitant medication with potential drug interaction with any of the study drugs such as alfuzosin, colchicine, ergot derivatives, cisapride, simvastatin and rifampicin - pregnant or lactating woman